252 results
Page 2 of 13
DEFM14A
7q5yn8l 52e
13 Apr 23
Proxy related to merger
4:52pm
424B5
g4zxlldmb
23 Sep 22
Prospectus supplement for primary offering
5:05pm
8-K
gzlfldemu3qcq
21 Sep 22
Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
4:10pm
8-K
EX-99.1
i0jml tke
21 Sep 22
Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
4:10pm
DEFA14A
zn7ctdjuu
18 Aug 22
Additional proxy soliciting materials
3:07pm
8-K
EX-99.1
r9deb3z28n8ne8dp87c
10 Aug 22
Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
nfsinpopp4sw kp5u
1 Aug 22
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
6:10am
8-K
l5i1uei 42zjv1gno7w
1 Aug 22
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
6:10am
DEFA14A
EX-10.1
xiaae
6 Jul 22
Additional proxy soliciting materials
6:04am
8-K
EX-10.1
sxj0imfx
6 Jul 22
Entry into a Material Definitive Agreement
6:04am
8-K
EX-10.1
hwm 4ujyd9
24 Jun 22
Entry into a Material Definitive Agreement
4:35pm
8-K
EX-3.1
v7myv5lvnunhtni dugv
17 Jun 22
Material Modifications to Rights of Security Holders
4:25pm
8-K
EX-10.2
sbhhl5tqllrfxw
18 May 22
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
7:53pm
8-K
EX-10.1
uubjp5ydo6 mzwa
18 May 22
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
7:53pm
8-K
EX-99.1
71uoaw39u ln3yowc
18 May 22
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
7:53pm